Abstract
Chronic myeloid leukaemia (CML) patients in chronic phase (CP) are currently treated with a standard dose of imatinib of 400 mg/daily. However, once in complete cytogenetic remission (CCR) it is possible that some patients maintain this status with reduced dose of the drug. Here, we describe five cases of CML in late CP, which were switched to imatinib while in CCR after interferon alpha (IFNα) and reached complete and stable molecular remission with intermittent drug administration at 400 mg/every 20 days/month.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have